Key Highlights

  • Eli Lilly (NYSE: LLY) secured rights to AlzeCure Pharma's ACD856 for over $1 billion.
  • The deal adds a novel Alzheimer's mechanism to Lilly's portfolio, complementing donanemab.
  • Alzheimer's market potential is estimated at $8-12 billion annually, rivaling obesity drugs.
  • Current analyst models largely overlook Lilly's Alzheimer's platform value.
  • This move could unlock $100-200 billion in unmodelled market capitalisation.

A Second Pillar for Growth

Eli Lilly and Company has once again signalled its ambition in the lucrative Alzheimer's market, announcing a licensing deal with AlzeCure Pharma valued at over $1 billion. This agreement grants Lilly global rights to AlzeCure's ACD856, a small molecule designed to modulate TrkA/BDNF signalling. The move is significant not only for its potential to address Alzheimer's disease through a distinct mechanism but also for bolstering Lilly's pipeline at a time when its GLP-1 agonists, such as tirzepatide, are projected to generate over $50 billion in peak revenue.

While the market's attention has been fixated on the transformative impact of GLP-1 drugs on obesity and diabetes, this latest acquisition underscores Lilly's strategy of building a diversified portfolio of blockbuster treatments. The inclusion of ACD856, which targets cognitive enhancement rather than amyloid plaque removal, positions Lilly to offer a comprehensive approach to Alzheimer's care.

Complementary Alzheimer's Strategy

The acquisition of ACD856 complements Lilly's existing Alzheimer's efforts, most notably donanemab, an anti-amyloid antibody that received FDA approval in 2025. Donanemab targets the underlying pathology of the disease by clearing amyloid plaques, a key hallmark of Alzheimer's. In contrast, ACD856 aims to improve cognitive function by stimulating the TrkA/BDNF pathway, which is crucial for neuronal survival and plasticity.

This dual-pronged approach, one addressing the disease's pathology and the other enhancing cognitive function, could prove highly synergistic. Analysts estimate that a combined Alzheimer's portfolio could capture an annual market of $8-12 billion. This burgeoning market is increasingly being viewed as the next frontier for pharmaceutical innovation, akin to the recent explosion in the obesity drug sector, with an estimated 6.7 million patients in the United States alone.

Unmodelled Value Creation

A critical aspect of the AlzeCure deal is its potential to unlock substantial value that is currently absent from Wall Street's financial models. Consensus estimates for Lilly's earnings in the 2026-2028 period predominantly focus on the projected revenues from its GLP-1 franchise. The significant investment in Alzheimer's, particularly with the addition of ACD856, represents an "optionality" that is not yet priced into the company's market capitalisation.

Analysts suggest this unmodelled potential could translate to $100-200 billion in additional market value. As donanemab begins to generate commercial revenue and clinical data emerges for ACD856, these assumptions will likely be incorporated into future earnings forecasts, potentially leading to a re-evaluation of Lilly's stock. The market size for Alzheimer's treatments is vast, and Lilly's proactive strategy positions it to be a dominant player.

Navigating the Competitive Landscape

The Alzheimer's drug market is highly competitive, with several pharmaceutical giants vying for a significant share. While Lilly's donanemab has gained regulatory traction, other companies are also advancing their candidates. The success of ACD856 will depend on its clinical efficacy, safety profile, and its ability to demonstrate a meaningful benefit for patients, particularly in combination with amyloid-clearing therapies.

AlzeCure's own research indicates that ACD856 targets amyloid beta protein, suggesting potential synergies or alternative applications within the amyloid pathway, although the primary narrative focuses on TrkA/BDNF signalling. The over $1 billion deal value reflects the perceived potential of ACD856 and the strategic importance of a diversified Alzheimer's approach. Lilly's established presence in neuroscience, coupled with its commercial prowess, provides a strong foundation for bringing this new therapy to market.